Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hafnium oxide - Nanobiotix

Drug Profile

Hafnium oxide - Nanobiotix

Alternative Names: Hafnium Oxide nanoparticles; Hensify; NBTX 3; NBTXR-3; PEP-503

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanobiotix
  • Developer LianBio; M. D. Anderson Cancer Center; Nanobiotix; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Radiosensitisers; Small molecules
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Squamous cell cancer
  • Phase II/III Soft tissue sarcoma
  • Phase I/II Rectal cancer; Solid tumours
  • Suspended Prostate cancer
  • No development reported Breast cancer; Cancer; Colorectal cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Inoperable/Unresectable, Second-line therapy or greater) in USA (Intratumoural, Injection)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Oesophageal-cancer(Combination therapy) in USA (Intratumoural, Injection)
  • 26 Dec 2023 LianBio and Janssen Pharmaceutica enters into a development and marketing agreement to develop and commercialize hafnium oxide in China, South Korea, Singapore and Thailand
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top